68 related articles for article (PubMed ID: 1436378)
1. Phenoxybenzamine selectively and irreversibly inactivates dopaminergic D2 receptors on primary cultured rat lactotrophs.
Shin SH; McAssey K; Heisler RL; Szabo MS
Neuroendocrinology; 1992 Sep; 56(3):397-406. PubMed ID: 1436378
[TBL] [Abstract][Full Text] [Related]
2. High concentrations of dopamine and epinephrine protect dopaminergic D2 receptors from inactivation by phenoxybenzamine on primary cultured rat lactotrophs.
Shin SH; Heisler RL
Neuroendocrinology; 1992 Sep; 56(3):407-14. PubMed ID: 1436379
[TBL] [Abstract][Full Text] [Related]
3. Activation of the adrenergic beta-receptor stimulates prolactin release from primary cultured pituitary cells.
Shin SH; Barton RE
Neuroendocrinology; 1993 Apr; 57(4):670-7. PubMed ID: 8396220
[TBL] [Abstract][Full Text] [Related]
4. Thyrotrophin-releasing hormone, vasoactive intestinal peptide, prolactin-releasing peptide and dopamine regulation of prolactin secretion by different lactotroph morphological subtypes in the rat.
Christian HC; Chapman LP; Morris JF
J Neuroendocrinol; 2007 Aug; 19(8):605-13. PubMed ID: 17620102
[TBL] [Abstract][Full Text] [Related]
5. Differential inhibition of dopamine and bromocriptine on induced prolactin release: multiple sites for the inhibition of dopamine.
Hanna S; Shin SH
Neuroendocrinology; 1992 May; 55(5):591-9. PubMed ID: 1316563
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of receptor inactivation, 17 beta-estradiol and pertussis toxin on dopaminergic inhibition of prolactin secretion in vitro.
Meller E; Puza T; Diamond J; Lieu HD; Bohmaker K
J Pharmacol Exp Ther; 1992 Nov; 263(2):462-9. PubMed ID: 1359107
[TBL] [Abstract][Full Text] [Related]
7. Receptor reserve for D2 dopaminergic inhibition of prolactin release in vivo and in vitro.
Meller E; Puza T; Miller JC; Friedhoff AJ; Schweitzer JW
J Pharmacol Exp Ther; 1991 May; 257(2):668-75. PubMed ID: 1674531
[TBL] [Abstract][Full Text] [Related]
8. Dopamine requires ascorbic acid to be the prolactin release-inhibiting factor.
Shin SH; Si F; Chang A; Ross GM
Am J Physiol; 1997 Sep; 273(3 Pt 1):E593-8. PubMed ID: 9316450
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin partially impedes the stimulatory effects of thyrotrophin-releasing hormone and dibutyryl cyclic AMP on prolactin release: prolactin release through multiple routes.
Shin SH; Heisler RL; Szabo MS
J Endocrinol; 1991 Jul; 130(1):79-86. PubMed ID: 1679101
[TBL] [Abstract][Full Text] [Related]
10. Inverse agonism at dopamine D2 receptors. Haloperidol-induced prolactin release from GH4C1 cells transfected with the human D2 receptor is antagonized by R(-)-n-propylnorapomorphine, raclopride, and phenoxybenzamine.
Nilsson CL; Ekman A; Hellstrand M; Eriksson E
Neuropsychopharmacology; 1996 Jul; 15(1):53-61. PubMed ID: 8797192
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic evidence that a D2 receptor subtype mediates dopaminergic stimulation of prolactin secretion from the anterior pituitary gland.
Burris TP; Stringer LC; Freeman ME
Neuroendocrinology; 1991 Aug; 54(2):175-83. PubMed ID: 1685014
[TBL] [Abstract][Full Text] [Related]
12. Functional Lactotroph Heterogeneity in Lactating Rats and in vitro Modification by 17Beta-Estradiol.
Zhang J; Chen C; Kukstas LA; Vincent JD; Israel JM
J Neuroendocrinol; 1990 Dec; 2(6):815-23. PubMed ID: 19215424
[TBL] [Abstract][Full Text] [Related]
13. Central administration of orexin A suppresses basal and domperidone stimulated plasma prolactin.
Russell SH; Kim MS; Small CJ; Abbott CR; Morgan DG; Taheri S; Murphy KG; Todd JF; Ghatei MA; Bloom SR
J Neuroendocrinol; 2000 Dec; 12(12):1213-8. PubMed ID: 11106980
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II receptors and prolactin release in pituitary lactotrophs.
Aguilera G; Hyde CL; Catt KJ
Endocrinology; 1982 Oct; 111(4):1045-50. PubMed ID: 6288343
[TBL] [Abstract][Full Text] [Related]
15. Biphasic action of forskolin on growth hormone and prolactin secretion by rat anterior pituitary cells in vitro.
Szabo M; Staib NE; Collins BJ; Cuttler L
Endocrinology; 1990 Oct; 127(4):1811-7. PubMed ID: 1698147
[TBL] [Abstract][Full Text] [Related]
16. Reexamination of dopamine as the prolactin-release inhibiting factor (PIF): supplementary agent may be required for dopamine to function as the physiological PIF.
Shin SH; Hanna SF; Hong M; Jhamandas K
Can J Physiol Pharmacol; 1990 Sep; 68(9):1226-30. PubMed ID: 1980429
[TBL] [Abstract][Full Text] [Related]
17. Reciprocal changes in prolactin and growth hormone secretion in vitro after in vivo estrogen treatment.
Horváth JE; Schally AV
Acta Biol Hung; 1994; 45(2-4):249-62. PubMed ID: 7725821
[TBL] [Abstract][Full Text] [Related]
18. Dopamine D2 receptor mediates both inhibitory and stimulatory actions on prolactin release.
Chang A; Shin SH; Pang SC
Endocrine; 1997 Oct; 7(2):177-82. PubMed ID: 9549043
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of anterior pituitary phosphoinositide phosphorylase activity by the D2 dopamine receptor.
Jarvis WD; Judd AM; MacLeod RM
Endocrinology; 1988 Dec; 123(6):2793-9. PubMed ID: 2904359
[TBL] [Abstract][Full Text] [Related]
20. The stimulatory and inhibitory effects of dopamine on prolactin secretion involve different G-proteins.
Burris TP; Nguyen DN; Smith SG; Freeman ME
Endocrinology; 1992 Feb; 130(2):926-32. PubMed ID: 1733734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
